Patents Examined by Zachary Skelding
  • Methods of administering anti-TNF? antibodies
    Patent number: 8889135
    Abstract: Methods of treating disorders in which TFN? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
    Type: Grant
    Filed: June 5, 2002
    Date of Patent: November 18, 2014
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Steven A. Fischkoff, Joachim Kempeni, Roberta Weiss
  • Methods for treating hematopoietic malignancies
    Patent number: 8883155
    Abstract: The present invention relates to methods for treating neoplasias in a mammalian subject. In particular, the invention provides methods for treating lymphomas, including forms of non-Hodgkin lymphoma. In one embodiment, these methods involve reducing tumor necrosis factor signaling.
    Type: Grant
    Filed: January 22, 2009
    Date of Patent: November 11, 2014
    Assignee: The Regents of the University of California
    Inventors: Michael David, Irene Munk Pedersen
  • Purified antibody composition
    Patent number: 8883156
    Abstract: The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.
    Type: Grant
    Filed: June 26, 2013
    Date of Patent: November 11, 2014
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Min M. Wan, George Avgerinos, Gregory Zarbis-Papastoitsis
  • Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherapy
    Patent number: 8883500
    Abstract: In the past, adoptive immunotherapy often failed because the transferred immune cells were inactive in vivo. This disclosure provides a method of producing immune cells that are highly active in vivo. The immune cells may be expanded in vitro in the presence of an adenosine receptor agonist or an antisense nucleic acid that downregulates expression of an adenosine receptor, for example. The immune cells may be tumor-infiltrating lymphocytes (TIL), cytotoxic T lymphocytes (CTL), natural killer (NK) cells, or lymphokine-activated killer (LAK) cells, for example. The methods described herein may be used to treat a number of diseases including cancer, infectious diseases, and immunodeficiencies.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: November 11, 2014
    Assignee: Northeastern University
    Inventors: Michail V. Sitkovsky, Akio Ohta
  • TNF-? binding proteins
    Patent number: 8877194
    Abstract: TNF-? binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind TNF-? are provided. Binding proteins have high affinity for TNF-? and neutralize TNF-? activity. A binding protein can be a full-length antibody or a TNF-?-binding portion thereof. Methods of making and methods of using the binding proteins are also described. The TNF-? binding proteins are useful for detecting TNF-? and for inhibiting TNF-? activity, including in a human subject suffering from a disease or disorder in which TNF-? activity is detrimental.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: November 4, 2014
    Assignee: AbbVie Inc.
    Inventors: Chung-ming Hsieh, Carrie L. Goodreau, Sahana Bose, Achim Moeller, Tariq Ghayur
  • Treatment drug for autoimmune diseases and allergic diseases
    Patent number: 8858944
    Abstract: The present invention provides an agent for the prophylaxis or therapy of autoimmune diseases or allergic diseases, which contains an anti-Embigin antibody, particularly an anti-Embigin antibody showing cytotoxicity or a cytotoxicity inducing activity, an agent for the prophylaxis or therapy of diseases involving Th17 cell, and a cytotoxic agent to Th17 cell. In addition, an agent for detection of Th17 cell, which contains an anti-Embigin antibody, a convenient detection method of Th17 cell, which uses the agent, a method of efficiently delivering a drug and the like in a Th17 cell selective manner, which uses an anti-Embigin antibody, and a drug delivery system to Th17 cell are provided.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: October 14, 2014
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Koichi Kino, Toshihiro Kai, Mitsuhiro Matsumoto, Masunori Kajikawa, Masahito Sugiura, Emi Shimizu
  • Human antibodies against human glycoprotein VI and their use
    Patent number: 8853368
    Abstract: Specific binding members directed to human glycoprotein VI (GPVI), in particular human antibodies, may employ the antibody VH and/or VL domain of the scFv fragment herein termed 10B12 or one or more complementarity determining regions (CDRs) of the 10B12 heavy chain variable (VH) and/or light chain variable (VL) domains, especially VH CDR3 in other antibody framework regions. Antibody molecules are provided with advantageous and unexpected properties, especially ability to inhibit collagen-induced platelet aggregation and the adhesion of platelets to Collagen-Related Peptide (CRP). Domain 1 of human GPVI is a primary target for the 10B12 antibody with these properties, and the epitope includes lysine 59.
    Type: Grant
    Filed: December 18, 2002
    Date of Patent: October 7, 2014
    Assignee: Cambridge Enterprise Limited
    Inventors: Peter Alexander Smethurst, Willem Hendrik Ouwehand, Richard William Farndale
  • Treatment of inflammatory bowel disease
    Patent number: 8852581
    Abstract: A method of treating inflammatory bowel disease (IBD) comprises collecting regulatory T cells in an activated or non-activated state from a patient's sentinel lymph nodes draining bowel segments with or without IBD, optionally activating the cells by contacting them with a cytokine and an antigen extract obtained from an inflamed bowel segment, expanding the T cells in vitro, and re-infusing the expanded T cell to the patient. Also disclosed are methods for obtaining sentinel nodes, for expanding T cells, for re-establishing the TH1/TH2 balance in the patient suffering from Crohn's disease, and corresponding uses of the expanded T cells, the cytokine and of antigen extract, as well as of correspondingly activated and expanded T cells.
    Type: Grant
    Filed: August 22, 2006
    Date of Patent: October 7, 2014
    Assignee: ITH Immune Therapy Holdings AB
    Inventors: Ola Winqvist, Magnus Thorn
  • Monoclonal antibodies against HMGB1
    Patent number: 8846047
    Abstract: In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.
    Type: Grant
    Filed: October 4, 2010
    Date of Patent: September 30, 2014
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Walter Newman, Shixin Qin, Theresa L. O'Keefe, Robert A. Obar
  • Low dose methods for treating disorders in which TNF? activity is detrimental
    Patent number: 8846046
    Abstract: A method of treating TNF? disorders is described, wherein the method comprises administering a low dose amount of a TNF? inhibitor.
    Type: Grant
    Filed: October 24, 2003
    Date of Patent: September 30, 2014
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Zehra Kaymakcalan, Robert Kamen
  • Methods for treating conditions associated with MASP-2 dependent complement activation
    Patent number: 8840893
    Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: September 23, 2014
    Assignees: Omeros Corporation, University of Leicester
    Inventors: Hans-Wilhelm Schwaeble, Clark E. Tedford, James B. Parent, Thomas Dudler, Gregory A. Demopulos
  • Antibodies to CD70
    Patent number: 8834882
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumor cell growth.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: September 16, 2014
    Assignee: arGEN-X B.V.
    Inventors: Karen Silence, Peter Ulrichts, Johannes Joseph Wilhelmus De Haard, Torsten Dreier, Michael John Scott Saunders, Harald Wajant, Sofie Maria Elvire Gabriels, Mahan Moshir
  • Methods for the therapy of inflammatory bowel disease using a type-1 interferon antagonist
    Patent number: 8828393
    Abstract: Compositions and methods for the therapy of Inflammatory Bowel Disease (IBD), including Celiac Disease, Crohn's Disease, and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more anti-type 1 interferon antagonists, such as anti-type 1 interferon receptor antibody antagonists and fragments thereof, as well as polypeptides and small molecules that inhibit the interaction of type 1 interferon with its receptor (IFNAR).
    Type: Grant
    Filed: March 17, 2011
    Date of Patent: September 9, 2014
    Assignee: Medarex, L.L.C.
    Inventors: Lesley B. Pickford, Christopher R. Bebbington, Geoffrey T. Yarranton, David King
  • Humanized anti-human NKG2A monoclonal antibody
    Patent number: 8796427
    Abstract: The present invention relates to agents that are non-competitive antagonists of the CD94/NKG2A receptor such as certain anti-NKG2A antibodies, in particular humanized versions of murine anti-NKG2A antibody Z199, as well as methods of producing and using such agents and antibodies.
    Type: Grant
    Filed: January 23, 2009
    Date of Patent: August 5, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Petrus Johannes Louis Spee, Jianhe Chen, Søren Berg Padkjær, Jing Su, Jinchao Zhang, Jiujiu Yu
  • Cd4+ Cd25+ T-cells activated to a specific antigen
    Patent number: 8785140
    Abstract: The invention relates to a method of assessing whether a subject comprises CD4+,CD25+ T cells that have been activated to a specific antigen. The method comprises the steps of obtaining from the subject a sample of lymphocytes comprising CD4+,CD25+ T cells, incubating at least one portion of the sample of lymphocytes so as to promote distinction of CD4+,CD25+ T cells that have been activated to the specific antigen from those CD4+,CD25+ T cells that have not been activated to the specific antigen, and thereafter determining whether CD4+,CD25+ T cells activated to the specific antigen are present in the sample. The invention further relates to methods of growing CD4+, CD25+ T cells that have been activated to a specific antigen in vitro and to methods of increasing tolerance in a subject using the CD4+, CD25+ T cells that have been grown in vitro.
    Type: Grant
    Filed: February 2, 2006
    Date of Patent: July 22, 2014
    Assignee: New South Innovations Pty Limited
    Inventors: Bruce M. Hall, Suzanne J. Hodgkinson
  • LAT adapter molecule for enhanced T-cell signaling and method of use
    Patent number: 8779095
    Abstract: LAT (Linker for Activation of T-cells) is a protein involved in signaling through the T-cell receptor (TCR). The invention provides a LAT protein including mutations at ubiquitylation sites that result in an increase in stability of LAT in stimulated and unstimulated cells, and enhanced signaling through the TCR. The invention further provides use for a LAT protein including mutations at ubiquitylation sites for therapeutic and laboratory methods.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: July 15, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Lawrence E. Samelson, Lakshmi Balagopalan
  • Antagonistic DR3 ligands
    Patent number: 8765130
    Abstract: The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: July 1, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Mette Dahl Andersen, Peder Lisby Noerby, Kristian Kjaergaard, Susanne Nedergaard Grell, Albrecht Gruhler, Jens Buchardt, Henrik Sune Andersen, Soeren Padkjaer, Jesper Kastrup, Katarina Haakansson, Lars Hornum, Birgitte Friedrichsen, Dorrit Baunsgaard
  • Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)
    Patent number: 8758757
    Abstract: Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: June 24, 2014
    Assignee: Medarex, L.L.C.
    Inventors: Josephine M. Cardarelli, Tseng-hui Timothy Chen, David King, Christopher R. Bebbington, Sarah Lee Pogue, Francis J. Carr, Stephen Williams
  • Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and uses thereof
    Patent number: 8728477
    Abstract: The present invention is directed to monoclonal, chimeric or humanized, antibodies or antibody-like molecules that recognize an epitope common to human acidic and basic isoferritins. The anti-ferritin antibodies or antibody-like molecules can be used in pharmaceutical compositions for immunotherapy or radioimmunotherapy to target various cancer cells in a mammal. A method for delivering anti-ferritin antibodies or antibody-like molecules to cancerous lymph cells, pancreatic cells, lymphatic endothelium cells, and liver cells is also disclosed, as well as methods for treating pancreatic cancer, hepatocellular carcinomas, Kaposi's sarcoma and Hodgkin's lymphoma.
    Type: Grant
    Filed: September 19, 2007
    Date of Patent: May 20, 2014
    Assignee: Immune Pharmaceuticals Ltd.
    Inventors: Jean Kadouche, Emmanuelle Sabbah-Petrover, Olivier Chose
  • T-cell receptor capable of recognising an antigen from cytomegalovirus
    Patent number: 8722048
    Abstract: The present invention provides a T-cell receptor (TCR) which binds to a peptide from the cytomegalovirus (CMV) phosphoprotein pp65 having the amino acid sequence NLVPMVATV (SEQ ID No. 1) when presented by a major histocompatability complex (MHC) molecule. The present invention also provides a nucleotide sequence encoding such a TCR, a vector comprising such a nucleotide sequence and its use to produce a CMV-specific T-cell. The present invention also provides the use of CMV-specific T-cell for cellular immunotherapy.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: May 13, 2014
    Assignee: UCL Business PLC
    Inventors: Hans Stauss, Shao-An Xue